Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study

Graff, J. N.; Burotto, M.; Fong, P. C.; Pook, D. W.; Zurawski, B.; Kopp, R. Manneh; Salinas, J.; Bylow, K. A.; Kramer, G.; Ratta, R.; Kwiatkowski, M.; Retz, M.; Kwak, C.; Arija, J. A. Arranz; Gurney, H.; Matsubara, N.; Villanueva, L.; Todenhofer, T.; Liang, L. W.; Todoric, J.; Imai, K.; Stenzl, A.

dc.contributor.author	Stenzl, Arnulf
dc.date.accessioned	2026-08-25T06:23:58Z
dc.date.available	2026-08-25T06:23:58Z
dc.date.issued	2025
dc.identifier.issn	0923-7534
dc.identifier.uri	http://hdl.handle.net/10900/182516
dc.language.iso	en	de_DE
dc.publisher	Amsterdam : Elsevier	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.annonc.2025.05.007	de_DE
dc.subject.ddc	610	de_DE
dc.title	Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study	de_DE
dc.type	Article	de_DE
utue.quellen.id	20251118000000_01511
utue.publikation.seiten	976-987	de_DE
utue.personen.roh	Graff, J. N.
utue.personen.roh	Burotto, M.
utue.personen.roh	Fong, P. C.
utue.personen.roh	Pook, D. W.
utue.personen.roh	Zurawski, B.
utue.personen.roh	Kopp, R. Manneh
utue.personen.roh	Salinas, J.
utue.personen.roh	Bylow, K. A.
utue.personen.roh	Kramer, G.
utue.personen.roh	Ratta, R.
utue.personen.roh	Kwiatkowski, M.
utue.personen.roh	Retz, M.
utue.personen.roh	Kwak, C.
utue.personen.roh	Arija, J. A. Arranz
utue.personen.roh	Gurney, H.
utue.personen.roh	Matsubara, N.
utue.personen.roh	Villanueva, L.
utue.personen.roh	Todenhofer, T.
utue.personen.roh	Liang, L. W.
utue.personen.roh	Todoric, J.
utue.personen.roh	Imai, K.
utue.personen.roh	Stenzl, A.
dcterms.isPartOf.ZSTitelID	Annals of Oncology	de_DE
dcterms.isPartOf.ZS-Issue	8	de_DE
dcterms.isPartOf.ZS-Volume	36	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE